Phase II Trial of Sunitinib in Bronchoalveolar Carcinoma or Never-Smokers With Any Lung Adenocarcinoma
To participate in this study, patients must have disease that can be measured on a CT scan.
Brain metastases are OK if stable. Pregnant and/or nursing women may not participate. This
drug has been approved by the FDA for the treatment of advanced renal cell cancer and a
certain type of stomach/intestinal cancer. Its efficacy in lung cancer in currently unknown.
Common side effects include fatigue, nausea, diarrhea, skin reaction, and decreased blood
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Howard West, M.D.
Swedish Cancer Institute
United States: Food and Drug Administration
|Swedish Cancer Institute||Seattle, Washington 98104|